(AALs) Acoustically active lipospheres and ultrasound are under development to deliver bioactive molecules to the vascular endothelium. The AALs are similar to both ultrasound contrast agents and drug-delivering liposomes. They can carry bioactive substances using biologically inert shells and deliver those substances when disrupted by ultrasound.
The lipospheres consist of a small gas microbubble surrounded by a thick oil shell and are enclosed by an outermost lipid layer. The gas bubble contained in these vehicles makes them acoustically active, similar to ultrasound contrast agents. Acoustically active lipospheres can be nondestructively deflected using ultrasound radiation force, and fragmented with high intensity ultrasound pulses. Their lipid-oil complex can carry bioactive substances at high concentrations. An optimized sequence of ultrasound pulses can deflect the AALs toward a vessel wall then disrupt them, painting their contents across the vascular endothelium.

See also Filling Gas, and MRX 115.

Any abnormal reaction of a patient to an examination or procedure, like for example side effects of contrast agents or claustrophobia. Claustrophobic attacks as can happen with MRI are unknown with ultrasound examinations. Adverse reactions with ultrasonic contrast agents are very infrequent. In general, adverse reactions increase with the quantity of contrast media and also with the osmolarity of the compound.
Most frequently encountered adverse reactions are: Heat sensation, dizziness, nausea, hypotension due to vasodilatation, which can progress to hypotensive shock and anaphylactic reactions.

The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group.
The company makes ultrasound, x-ray and MRI contrast media, drugs for treating cancer, multiple-sclerosis, heart and nervous system disorders and severe skin conditions.
In general, its activities are focused on four business areas: Fertility control & hormone therapy, diagnostics & radiopharmaceuticals, dermatology as well as specialized therapeutics for disabling diseases in the fields of the central nervous system, oncology and cardiovascular system.
Currently, Bayer Schering Pharma discontinued the manufacturing and development of ultrasound contrast agents.

Ultrasound Contrast Agents:

Cavitation is any activity of highly compressible transient or stable microbubbles of gas and/or vapour, generated by ultrasonic power in the propagation medium. Cavitation can be described as inertial or non-inertial. Inertial cavitation has the most potential to damage tissue and occurs when a gas-filled cavity grows, during pressure rarefaction of the ultrasound pulse, and contracts, during the compression phase. Collapses of bubbles can generate local high temperatures and pressures. Transient cavitation can cause tissue damage.
The threshold for cavitation is high and does not occur at current levels of diagnostic ultrasound. The introduction of contrast agents leads to the formation of microbubbles that potentially provide gas nuclei for cavitation. The use of contrast agents can lower the threshold at which cavitation occurs.

Types of cavitation:

Contrast agents improve the sensitivity of vascular Doppler ultrasound, for example in cerebrovascular sonography or examinations of deep abdominal vessels. They also enlarge the role of transcranial Doppler. Microbubbles can be used with various modes e.g., color and power Doppler imaging, as well as pulsed-wave Doppler to increase the signal intensity. However, the ultrasound system must be suitable for contrast enhanced technology.
Microbubbles usually stay within the vascular space; nevertheless, the contrast enhancement is limited to 2−6 minutes caused by physiologic clearance and bubble destruction.
Depended on the application, contrast agents can be administered with a different injection rate e.g., bolus injection, slow injection, or continuous infusion. Stable, homogeneous, and prolonged enhancement can be obtained with perfusion, lasting until the infusion is stopped.

See also Cerebrovascular Ultrasonography, Multiple Frame Trigger.